"Polycythemia Vera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Descriptor ID |
D011087
|
| MeSH Number(s) |
C04.588.448.200.500 C15.378.190.250.500 C15.378.190.636.753 C15.378.400.200.500
|
| Concept/Terms |
Polycythemia Vera- Polycythemia Vera
- Primary Polycythemia
- Polycythemia, Primary
- Polycythemias, Primary
- Primary Polycythemias
- Polycythemia Rubra Vera
- Polycythemia Rubra Veras
- Vera, Polycythemia Rubra
- Veras, Polycythemia Rubra
- Polycythemia Ruba Vera
- Polycythemia Ruba Veras
- Ruba Vera, Polycythemia
- Ruba Veras, Polycythemia
- Vera, Polycythemia Ruba
- Veras, Polycythemia Ruba
- Osler-Vaquez Disease
- Disease, Osler-Vaquez
- Osler Vaquez Disease
- Erythremia
- Erythremias
|
Below are MeSH descriptors whose meaning is more general than "Polycythemia Vera".
Below are MeSH descriptors whose meaning is more specific than "Polycythemia Vera".
This graph shows the total number of publications written about "Polycythemia Vera" by people in this website by year, and whether "Polycythemia Vera" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 11 | 3 | 14 |
| 2008 | 2 | 1 | 3 |
| 2009 | 5 | 0 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 5 | 1 | 6 |
| 2014 | 7 | 0 | 7 |
| 2015 | 13 | 2 | 15 |
| 2016 | 9 | 1 | 10 |
| 2017 | 14 | 3 | 17 |
| 2018 | 4 | 0 | 4 |
| 2019 | 2 | 2 | 4 |
| 2020 | 5 | 0 | 5 |
| 2021 | 2 | 0 | 2 |
| 2022 | 7 | 0 | 7 |
| 2023 | 7 | 0 | 7 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Polycythemia Vera" by people in Profiles.
-
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024 Jul; 25(10):1391-1404.
-
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22; 390(8):723-735.
-
Moving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.
-
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera. Expert Rev Hematol. 2023 05; 16(5):305-316.
-
Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. Blood Adv. 2023 03 14; 7(5):712-717.
-
Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023 04; 127:107033.
-
A review of essential thrombocythemia and its complications. Clin Adv Hematol Oncol. 2023 Feb; 21(2):76-84.
-
Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol. 2023 Mar; 102(3):571-581.
-
Ischemic Jejunal Stricture Secondary to Polycythemia Vera. Dig Dis Sci. 2023 04; 68(4):1077-1079.
-
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 09; 20(9):1033-1062.